These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 8426016

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 3. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
    Golino P, Ambrosio G, Gresele P, Pascucci I, Ragni M, Russolillo E, Leproux GB, Chiariello M.
    J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
    [Abstract] [Full Text] [Related]

  • 4. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS, Wharton KA, White BP, Lumley P.
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [Abstract] [Full Text] [Related]

  • 5. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G, Hermans C, Somers Y, Van de Werf F, de Clerck F.
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Apr; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA.
    Thromb Haemost; 1989 Feb 28; 61(1):43-9. PubMed ID: 2526385
    [Abstract] [Full Text] [Related]

  • 9. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P, Giordani A, Menichincheri M, Pillan A, Pinciroli V, Rossi A, Tonani R, Volpi D, Tamburin M, Ferrario R.
    J Med Chem; 1994 Oct 14; 37(21):3588-604. PubMed ID: 7932586
    [Abstract] [Full Text] [Related]

  • 10. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
    Mullane KM, Fornabaio D.
    Circ Res; 1988 Apr 14; 62(4):668-78. PubMed ID: 3127073
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 14; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb 14; 89(2):588-95. PubMed ID: 8313547
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C.
    J Pharmacol Exp Ther; 1994 Apr 14; 269(1):238-45. PubMed ID: 8169831
    [Abstract] [Full Text] [Related]

  • 17. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
    Grover GJ, Schumacher WA, Simon M, Parham C.
    J Cardiovasc Pharmacol; 1988 Dec 14; 12(6):701-9. PubMed ID: 2467089
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM, Wu TS, Teng CM.
    Br J Pharmacol; 1994 Mar 14; 111(3):906-12. PubMed ID: 8019768
    [Abstract] [Full Text] [Related]

  • 19. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R, Mezzasoma AM, Venditti G, Gresele P.
    Thromb Haemost; 2002 Jan 14; 87(1):114-21. PubMed ID: 11848439
    [Abstract] [Full Text] [Related]

  • 20. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F.
    Thromb Haemost; 1992 Aug 03; 68(2):214-20. PubMed ID: 1412169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.